Krystal Biotech (KRYS) Revenue (2023 - 2026)

Krystal Biotech (KRYS) has 4 years of Revenue data on file, last reported at $116.4 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 32.0% year-over-year to $116.4 million; the trailing twelve-month figure through Mar 2026 stood at $417.3 million (up 25.16% YoY), and the FY2025 full-year result was $389.1 million, up 33.94% from the prior year.
• Revenue rose to $116.4 million in Q1 2026, from $107.1 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $116.4 million in Q1 2026 to a low of $8.6 million in Q3 2023.
• A 4-year average of $77.0 million and a median of $88.2 million in 2025 frame the typical range for Revenue.
• Across the five-year window, Revenue soared 879.91% in 2024 and rose 16.65% in 2025, its largest moves.
• Tracing KRYS's Revenue over 4 years: stood at $42.1 million in 2023, then surged by 116.26% to $91.1 million in 2024, then rose by 17.52% to $107.1 million in 2025, then advanced by 8.68% to $116.4 million in 2026.
• Business Quant data shows KRYS's Revenue at $116.4 million in Q1 2026, $107.1 million in Q4 2025, and $97.8 million in Q3 2025.